Please login to the form below

Not currently logged in
Email:
Password:

Astellas files lawsuit against Nycomed

Astellas has filed a patent infringement lawsuit in the US against Nycomed in relation to Protopic, an eczema medicated ointment

Japanese pharmaceutical company Astellas has filed a patent infringement lawsuit in the US against Nycomed in relation to Protopic (tacrolimus), an eczema medicated ointment.

The lawsuit has been filed as a result of Nycomed submitting an abbreviated new drug application (ANDA) to the US Food and Drug Administration (FDA) for a generic version of Protopic – Astellas' 0.1 per cent tacrolimus ointment.

Astellas filed the patent infringement action in the US District Court for the District of New Jersey on October 27, 2010. Astellas is petitioning for Nycomed's ANDA not to be approved before the expiration of two patents held by Astellas in relation to Protopic.

Protopic ointment is indicated for the treatment of moderate to severe eczema and has been approved for use in the US since the end of 2000. Protpoic is available in two dosage strengths – 0.1 per cent and 0.03 per cent. It is recommended that children aged between two and 15 years should only receive the 0.03 per cent strength of the ointment.

28th October 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics